Intrathecal magnesium delivery for Mg++-insensitive NMDA receptor activity due to GRIN1 mutation
Orphanet journal of rare diseases(2023)
摘要
Background Mutations in the NMDA receptor are known to disrupt glutamatergic signaling crucial for early neurodevelopment, often leading to severe global developmental delay/intellectual disability, epileptic encephalopathy, and cerebral palsy phenotypes. Both seizures and movement disorders can be highly treatment-refractory. Results We describe a targeted ABA n-of-1 treatment trial with intrathecal MgSO 4 , rationally designed based on the electrophysiologic properties of this gain of function mutation in the GRIN1 NMDA subunit. Conclusion Although the invasive nature of the trial necessitated a short-term, non-randomized, unblinded intervention, quantitative longitudinal neurophysiologic monitoring indicated benefit, providing class II evidence in support of intrathecal MgSO 4 for select forms of GRIN disorders.
更多查看译文
关键词
/Terms epileptic encephalopathy,Cerebral palsy,Dystonia,Neurodevelopmental Disorders,GRIN Disorders,NMDA receptor,Precision Medicine,N-of-1 treatment trial
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要